EYLEA4U®: Comprehensive Support for You and Your Patients

We're here to help you with patient support, reimbursement assistance, and access solutions for EYLEA

EYLEA4U is committed to help ensure your eligible patients have access to EYLEA regardless of insurance or coverage. Use our wide range of resources to help your patients access EYLEA and address any questions you might have.

ICD-10 code finder

Use the interactive code finder to quickly find the current ICD-10 codes for EYLEA. To begin, simply answer the following short questions.

The coding information discussed here is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed here may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

For which indication is EYLEA being administered?

Popular resources see all

We are here for you in person, online, or by phone

Your office has a dedicated Regional Business Manager and Medical Specialist who are always available for in-office support.

Call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248) Monday–Friday 9 AM–8 PM Eastern Time.

Healthcare provider medical
information inquiries
Patient or caregiver medical
information inquiries

Adverse events,
product complaints,
and product returns

Reimbursement and patient
assistance support
Product-ordering
assistance through
one of our distributors

EYLEA4U e-Portal: Your one-stop, online destination for reimbursement and patient support

The EYLEA4U e-Portal is an efficient, secure, and convenient tool for enrolling and managing patients in our support programs. The portal is available online for instant access to patient case status updates.*

Visit the portal

*Requires registration and e-signature setup.

Product support

EYLEA (aflibercept) Injection 2 mg/0.05 mL single-use vial and packaging

With EYLEA comes complete product support. Find all the information you need for ordering EYLEA, requesting a return, getting a discount, and more—and EYLEA4U is available to guide you through it.

Learn how it works

Navigating reimbursement

EYLEA4U is here to help you through the entire reimbursement process. Easily download enrollment forms, learn about prior authorization requirements, find sample appeal letters, and more.

Start the process

Patient Support

EYLEA4U is committed to help ensure your eligible patients have access to
EYLEA regardless of insurance or coverage. Our programs include*:

Co-pay card program for EYLEA cost assistance

EYLEA Co-Pay Card Program

With the EYLEA Co-Pay Card, patients with
commercial healthcare coverage may be eligible
to pay as little as a $0 co-pay for each EYLEA
treatment. Subject to annual assistance limit.^†

See the program

Co-Pay Assistance Referral

EYLEA4U can provide
information about the referral process, which connects patients in need to independent charitable foundations.^‡

Learn about the process

Eligible patients can receive EYLEA at no cost

Patient Assistance Program

No insurance or no coverage for EYLEA? No problem. The Patient Assistance Program (PAP) from EYLEA4U can provide EYLEA free of charge to your eligible patients.^§

Get more information

*Program conditions apply.
^†Subject to annual assistance limit. Co-pay reimbursement is subject to an annual cap, and the patient is responsible for any additional co-pay costs that exceed the program assistance limit. This program is not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or similar federal or state programs. This program is not an insurance benefit. The program does not cover or provide support for supplies, procedures, or any physician-related service associated with EYLEA. General, non–product-specific co-pay, co-insurance, or insurance deductibles are not covered. This program is not valid where prohibited by law, taxed, or restricted. EYLEA4U reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional program conditions apply.
^‡Regeneron does not influence or control the operations of independent charitable foundations and cannot guarantee assistance will be provided. Subject to Regeneron policies.
^§Household income limits apply.

Important Safety Information

EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.
Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

INDICATIONS

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

Accessing EYLEA